Mesoblast Stock Performance
| MEOBF Stock | USD 1.90 0.55 40.74% |
On a scale of 0 to 100, Mesoblast holds a performance score of 5. The company secures a Beta (Market Risk) of 0.98, which conveys possible diversification benefits within a given portfolio. Mesoblast returns are very sensitive to returns on the market. As the market goes up or down, Mesoblast is expected to follow. Please check Mesoblast's kurtosis, as well as the relationship between the day median price and period momentum indicator , to make a quick decision on whether Mesoblast's current price movements will revert.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Mesoblast are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile fundamental drivers, Mesoblast reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 136.9 M | |
| Total Cashflows From Investing Activities | -232 K |
Mesoblast |
Mesoblast Relative Risk vs. Return Landscape
If you would invest 160.00 in Mesoblast on September 28, 2025 and sell it today you would earn a total of 30.00 from holding Mesoblast or generate 18.75% return on investment over 90 days. Mesoblast is currently producing 0.6359% returns and takes up 8.4344% volatility of returns over 90 trading days. Put another way, 75% of traded pink sheets are less volatile than Mesoblast, and 88% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Mesoblast Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mesoblast's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Mesoblast, and traders can use it to determine the average amount a Mesoblast's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0754
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | MEOBF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Mesoblast is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Mesoblast by adding it to a well-diversified portfolio.
Mesoblast Fundamentals Growth
Mesoblast Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Mesoblast, and Mesoblast fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mesoblast Pink Sheet performance.
| Return On Equity | -0.16 | |||
| Return On Asset | -0.0688 | |||
| Operating Margin | (9.53) % | |||
| Current Valuation | 504.31 M | |||
| Shares Outstanding | 736.58 M | |||
| Price To Earning | (6.34) X | |||
| Price To Book | 0.92 X | |||
| Price To Sales | 68.10 X | |||
| Revenue | 10.21 M | |||
| EBITDA | (70.3 M) | |||
| Cash And Equivalents | 60.45 M | |||
| Cash Per Share | 0.08 X | |||
| Total Debt | 91.62 M | |||
| Debt To Equity | 0.21 % | |||
| Book Value Per Share | 0.71 X | |||
| Cash Flow From Operations | (65.78 M) | |||
| Earnings Per Share | (0.14) X | |||
| Total Asset | 662.14 M | |||
| Retained Earnings | (288 M) | |||
| Current Asset | 71 M | |||
| Current Liabilities | 31 M | |||
About Mesoblast Performance
By analyzing Mesoblast's fundamental ratios, stakeholders can gain valuable insights into Mesoblast's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Mesoblast has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Mesoblast has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia. Mesoblast operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 77 people.Things to note about Mesoblast performance evaluation
Checking the ongoing alerts about Mesoblast for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Mesoblast help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Mesoblast is way too risky over 90 days horizon | |
| Mesoblast may become a speculative penny stock | |
| Mesoblast appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 10.21 M. Net Loss for the year was (91.35 M) with loss before overhead, payroll, taxes, and interest of (53.36 M). | |
| Mesoblast has accumulated about 60.45 M in cash with (65.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08. |
- Analyzing Mesoblast's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mesoblast's stock is overvalued or undervalued compared to its peers.
- Examining Mesoblast's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Mesoblast's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mesoblast's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Mesoblast's pink sheet. These opinions can provide insight into Mesoblast's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Mesoblast Pink Sheet analysis
When running Mesoblast's price analysis, check to measure Mesoblast's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mesoblast is operating at the current time. Most of Mesoblast's value examination focuses on studying past and present price action to predict the probability of Mesoblast's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mesoblast's price. Additionally, you may evaluate how the addition of Mesoblast to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |